Funding news · Oct 9, 2026
Sava Technologies Raises $36M Series B Led by Ascensia Diabetes Care
Sava Technologies Closes $36M Series B
Sava Technologies has raised a $36 million Series B round, the company confirmed. The round was led by Ascensia Diabetes Care, with participation from Simplyhealth Ventures, Norrsken VC, JamJar Investments, Pentland Ventures, and Balderton Capital.
What Sava Technologies Does
Sava Technologies develops a wearable biosensor platform powered by proprietary microsensing technology. The platform is designed to detect multiple biomarkers just under the skin in real time.
The company's first product is a Continuous Glucose Monitor (CGM). According to the company, the device is pain-free, low-cost, and accurate, and it delivers molecular insights directly to a user's smartphone.
The Round at a Glance
- Company: Sava Technologies
- Round type: Series B
- Amount raised: $36,000,000 USD
- Lead investor: Ascensia Diabetes Care
- Additional investors: Simplyhealth Ventures, Norrsken VC, JamJar Investments, Pentland Ventures, Balderton Capital
- Announcement date: October 9, 2026
Why the Raise Matters
The Series B positions Sava to advance a biosensor platform that targets the continuous glucose monitoring market, where real-time molecular data delivered to a smartphone is the core value proposition. The participation of Ascensia Diabetes Care as lead investor places a strategic player in diabetes care at the center of the round.
The investor syndicate combines specialist healthcare and life-science backers in Simplyhealth Ventures and Ascensia Diabetes Care with generalist venture firms including Norrsken VC, JamJar Investments, Pentland Ventures, and Balderton Capital.
Platform and Product Focus
Sava's stated approach centers on microsensing technology that operates just beneath the skin. Rather than a single-purpose device, the company describes the platform as capable of detecting multiple biomarkers in real time, with the CGM as the first commercial application.
The company emphasizes three attributes for its CGM: it is pain-free, low-cost, and accurate. Data is delivered directly to a user's smartphone, keeping the user interface on hardware consumers already own.
What to Watch
With a $36 million Series B in hand and a strategic lead investor, Sava Technologies is capitalized to push its wearable biosensor platform and its first CGM product forward. For observers tracking the continuous glucose monitoring space, the company's combination of a multi-biomarker sensing platform and a low-cost device strategy is the central story to follow.
All figures and investor details are as reported in the funding announcement dated October 9, 2026.